162 related articles for article (PubMed ID: 37691869)
1. Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China.
Zhu Q; Ni R; Guan X
Transl Lung Cancer Res; 2023 Aug; 12(8):1782-1789. PubMed ID: 37691869
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.
Gong J; Wan Q; Shang J; Qian X; Su D; Sun Z; Liu G
Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
[TBL] [Abstract][Full Text] [Related]
3. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
Huo G; Liu W; Kang S; Chen P
Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China.
Fei Z; Rui M; Wang Y; Ma A
Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):79-87. PubMed ID: 36333963
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.
Lin J; Fang Q; Zheng X
PLoS One; 2023; 18(2):e0281402. PubMed ID: 36749752
[TBL] [Abstract][Full Text] [Related]
7. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Shu Y; Ding Y; Li F; Zhang Q
Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
Liu H; Wang Y; He Q
Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.
Li W; Wan L
Front Public Health; 2022; 10():1015702. PubMed ID: 36408023
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
Zhang C; Liu Y; Tan J; Tian P; Li W
Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Li S; Li J; Peng L; Li Y; Wan X
Front Oncol; 2021; 11():684073. PubMed ID: 34136409
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
Li Y; Liang X; Yang T; Guo S; Chen X
Front Oncol; 2022; 12():878054. PubMed ID: 36226060
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
Shi Y; Pei R; Liu S
Front Oncol; 2022; 12():833773. PubMed ID: 36324594
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.
Lu T; Huang Y; Cai Z; Lin W; Chen X; Chen R; Hu Y
Front Pharmacol; 2023; 14():1171302. PubMed ID: 37564176
[No Abstract] [Full Text] [Related]
20. First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis.
Liu W; Huo G; Li M; Chen P
Transl Lung Cancer Res; 2023 Sep; 12(9):1949-1958. PubMed ID: 37854153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]